Translational Medicine

Rising antimicrobial resistance challenges our ability to combat bacterial infections. The problem is acute for tuberculosis (TB), the leading cause of death from infection before COVID-19. Here, we developed a framework for multiple pharmaceutical companies to share proprietary information and compounds with multiple laboratories in the academic and government sectors for a broad examination of the ability of β-lactams to kill Mycobacterium tuberculosis (Mtb). In the TB Drug Accelerator (TBDA), a consortium organized by the Bill & Melinda Gates Foundation, individual pharmaceutical companies collaborate with academic screening laboratories. We developed a higher order consortium within the TBDA in which four pharmaceutical companies (GlaxoSmithKline, Sanofi, MSD, and Lilly) collectively collaborated with screeners at Weill Cornell Medicine, the Infectious Disease Research Institute (IDRI), and the National Institute of Allergy and Infectious Diseases (NIAID), pharmacologists at Rutgers University, and medicinal chemists at the University of North Carolina to screen ∼8900 β-lactams, predominantly cephalosporins, and characterize active compounds. In a striking contrast to historical expectation, 18% of β-lactams screened were active against Mtb, many without a β-lactamase inhibitor. One potent cephaloporin was active in Mtb-infected mice. The steps outlined here can serve as a blueprint for multiparty, intra- and intersector collaboration in the development of anti-infective agents.

show abstract

Innovative profile of the Russian pharmaceutical industry

Podshivalova

Pylaeva

Almrshed

2021

Vopr. èkon.

View full text Add to dashboard Cite

InnoThe article examines the specifics of innovative activity of Russian drug manufacturers, which in the context of a COVID-19 pandemic become a matter of national security. The research is based on panel data: out of a total of 1,816 enterprises in the industry, a sample of 345 innovatively active enterprises is formed with a time series of data 20 years long. The sample is diversified by the scale of enterprise activity into 4 groups: micro enterprises, small, medium, and large enterprises. These types of enterprises are compared both in absolute terms — size of investments in intangible assets, age, and in relative ones — frequency of investments in innovations, coefficient of autonomy, profitability of sales and assets, share of intangible assets in revenue and assets. The analysis was supplemented by enterprises not included in the sample to identify the effectiveness of innovation in the industry. The result is the innovative profile of industrial enterprises in the context of the scale of their activities. The conclusion is drawn about the specifics of the domestic pharmaceutical industry innovation activity, which generally coincides with the established distribution of roles in the global pharmaceutical industry, when large enterprises are leaders in the innovations development and implementation. Russian large companies also tend to use micro enterprises to implement risky projects. The authors conclude that in Russia, the foundations have been formed for transition to a new model of pharmaceutical industry innovative development. This model is based on cooperation of small and large businesses.

show abstract

Translational Medicine

Cited by 3 publications

References 39 publications

A Practical Guide to Translating Nanomedical Products

A Practical Guide to Translating Nanomedical Products

Identification of β-Lactams Active against Mycobacterium tuberculosis by a Consortium of Pharmaceutical Companies and Academic Institutions

Innovative profile of the Russian pharmaceutical industry

Contact Info

Product

Resources

About